(Image credit: Smith Collection/Gado/Getty Images)
The market for initial public offerings (IPOs) was gaining momentum heading into the fourth quarter of 2025, but quickly lost steam as the record-long government shutdown put a short-term halt to public offerings.
According to Renaissance Capital, the 64 IPOs we saw in Q3 raised a combined $15.3 billion, marking the biggest quarter of new issuance since 2021.
“Twenty-four IPOs raised $100 million or more, another post-2021 high, led by a wave of high-profile unicorns,” wrote Renaissance Capital in its Q3 2025 Quarterly Review (pdf). “Renewed interest in growth stocks allowed many of these names to price above the midpoint, and while a few of the earlier IPOs had explosive debuts, like billion-dollar deal Figma’s historic 250% pop, more rational appetite prevailed towards quarter end.”
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
CLICK FOR FREE ISSUE
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more – straight to your e-mail.
Profit and prosper with the best of expert advice – straight to your e-mail.
But October saw just 22 new listings, and November had half that, with the 33 total offerings raising a combined $5.5 billion.
And while Renaissance Capital does not expect a rush of offerings through year’s end “due to a backlogged SEC, pressure on AI and other tech stocks, and the approaching holiday slowdown,” there are several names in the pipeline that could make their market debut before the new year.
Among them is medical supplies company Medline, whose estimated deal size of $5 billion will make it the biggest IPO since Rivian Automotive (RIVN) raised $11.9 billion in its 2021 offering.
When is the Medline IPO?
In late October, Medline announced that it had filed its IPO paperwork with the Securities and Exchange Commission (SEC), though no specifics were given as to the number of shares it plans to issue or the price range for the offering.
While the exact date of the Medline IPO is unknown, the company is expected to start trading its stock on the Nasdaq Global Select Market under the ticker symbol “MDLN” at some point over the next few weeks.
Who owns Medline?
Medline previously traded on the public markets in the mid-1970s, but was taken private by Jim and Jon Mills, who founded the company in 1966.
In 2021, a group of private equity firms – Blackstone, Carlyle and Hellman & Friedman – acquired a majority stake in Medline for roughly $30 billion, in what was then the largest leveraged buyout since 2008.
According to the company’s regulatory filing, Medline currently operates 22 manufacturing facilities and 69 distribution centers across more than 100 countries. It employs 43,000 folks worldwide.
Its growth is impressive too. The company has enjoyed more than 50 straight years of annual net sales growth. In 2024, Medline generated net sales of $25.5 billion, up 10% from the year prior. And in the first six months of 2025, net sales rose 9.8% to $13.5 billion.
Can I buy MDLN stock?
“An initial public offering enables a private company to ‘go public,’ or start trading in public markets, by issuing its own shares on a stock exchange for the first time. In this way, any investor can buy shares and the company can raise capital to grow,” Kiplinger contributing writer Tom Taulli writes in his article, “What Is an Initial Public Offering (IPO)?”.
But buyer beware: IPOs can be volatile — especially for retail investors. While new stocks tend to have strong first-day showings, returns for the first year are generally weak, says the team of analysts at Trivariate Research, a market research firm based in New York.
“In this froth and frenzy, opportunities mix with peril,” writes David Milstead, senior associate editor at the Kiplinger Personal Finance magazine. “The safest course may be to wait for companies to settle in some months after their debut, after one or two quarterly earnings reports.”
Ultimately, the decision to buy the Medline IPO comes down to your own risk tolerance and personal investing goals. If you do choose to buy shares of MDLN stock when they first begin trading, it’s prudent to do so in a small amount that you can afford to lose and have a trading plan in place.
